| 1 |
Reddy DS, Sinha A, Kumar A, Saini VK. Drug re-engineering and repurposing: A significant and rapid approach to tuberculosis drug discovery. Arch Pharm (Weinheim) 2022;:e2200214. [PMID: 35841594 DOI: 10.1002/ardp.202200214] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 2 |
Sharma A, Agrahari AK, Rajkhowa S, Tiwari VK. Emerging impact of triazoles as anti-tubercular agent. Eur J Med Chem 2022;238:114454. [PMID: 35597009 DOI: 10.1016/j.ejmech.2022.114454] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 3 |
Cheke RS, Patil VM, Firke SD, Ambhore JP, Ansari IA, Patel HM, Shinde SD, Pasupuleti VR, Hassan MI, Adnan M, Kadri A, Snoussi M. Therapeutic Outcomes of Isatin and Its Derivatives against Multiple Diseases: Recent Developments in Drug Discovery. Pharmaceuticals 2022;15:272. [DOI: 10.3390/ph15030272] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 4 |
Malah TE, Farag H, Hemdan BA, Abdel Mageid RE, Abdelrahman MT, El-manawaty MA, Nour HF. Synthesis, in vitro antimicrobial evaluation, and molecular docking studies of new isatin-1,2,3-triazole hybrids. Journal of Molecular Structure 2022;1250:131855. [DOI: 10.1016/j.molstruc.2021.131855] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 5 |
Liu Y, Li C, Chen J, Han Y, Wei M, Liu J, Yu X, Li F, Hu P, Fu L, Liu Y. Electrospun high bioavailable rifampicin–isoniazid-polyvinylpyrrolidone fiber membranes. Appl Nanosci 2021;11:2271-80. [DOI: 10.1007/s13204-021-01957-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 6 |
Tan Z, Deng J, Ye Q, Zhang Z. Triazole-containing hybrids with anti-Mycobacterium tuberculosis potential - Part I: 1,2,3-Triazole. Future Med Chem 2021;13:643-62. [PMID: 33619989 DOI: 10.4155/fmc-2020-0301] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 7 |
Kumar R, Takkar P. Repositioning of Isatin hybrids as novel anti-tubercular agents overcoming pre-existing antibiotics resistance. Med Chem Res 2021;30:847-76. [DOI: 10.1007/s00044-021-02699-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 8 |
Sert Y, El-hiti GA, Gökce H, Ucun F, Abdel-wahab BF, Kariuki BM. DFT, molecular docking and experimental FT-IR, laser-Raman, NMR and UV investigations on a potential anticancer agent containing triazole ring system. Journal of Molecular Structure 2020;1211:128077. [DOI: 10.1016/j.molstruc.2020.128077] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 9 |
Zhang Y, Du H, Liu H, He Q, Xu Z. Isatin dimers and their biological activities. Arch Pharm Chem Life Sci 2020;353:1900299. [DOI: 10.1002/ardp.201900299] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 10 |
Ding Z, Zhou M, Zeng C. Recent advances in isatin hybrids as potential anticancer agents. Arch Pharm (Weinheim) 2020;353:e1900367. [PMID: 31960987 DOI: 10.1002/ardp.201900367] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 12.3] [Reference Citation Analysis]
|
| 11 |
Hou Y, Shang C, Wang H, Yun J. Isatin-azole hybrids and their anticancer activities. Arch Pharm (Weinheim) 2020;353:e1900272. [PMID: 31691360 DOI: 10.1002/ardp.201900272] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
|
